iTeos Therapeutics SA

iTeos Therapeutics is a privately-held, biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. Based in Gosselies, Belgium and in Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011, iTeos has completed a $75M round B with MPM Capital as lead investor in June 2018.